IL-5 Blocker: Mepolizumab, Reslizumab
IL-5 Receptor blocker: Benralizumab
markedly reduce blood and tissue eosinophils
and reduce exacerbations in patients who have persistently
increased sputum eosinophils despite maximal ICS therapy